Smith & Nephew (LSE: SN, NYSE: SNN), the global medical
technology business, today announces the European launch of
MolecuLight i:XTM, the easy to use, handheld imaging device
that instantly measures wound surface area and visualises the
presence and distribution of potentially harmful bacteria in
wounds.2,3
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171211005434/en/
Currently wound assessments are made with the naked eye which
can lack the accuracy required to most effectively guide clinical
decision making.4 Using fluorescence, MolecuLight i:X
quickly, safely, and easily visualises potentially harmful
bacteria1,2,3 in wounds which may otherwise lack signs or symptoms
of infection. It enhances a clinician’s ability to choose the right
therapy, at the right time for their patient1,2 and can help to
guide wound sampling and debridement,1,5,6 monitor wound
progression,2,3 improve patient engagement4,5 and simplify wound
documentation.1
Clinical data from wound assessments demonstrates that
incorporating the MolecuLight i:X into standard care
facilitated more objective medical decision making and led to up to
9 times faster wound healing1 and 54% more accurate swabbing.7
“The MolecuLight i:X enables healthcare professionals to
see what they have never been able to see before“ said Paolo Di
Vincenzo, Smith & Nephew’s Senior Vice President Global
Marketing, Wound. “We are proud to partner with MolecuLight Inc.
and bring this innovative technology to our customers. It strongly
complements our range of advanced wound care products and we
believe is set to start a revolution in wound care clinical
practice.”
“For the first time clinicians can accurately sample a wound in
situ to determine if bacteria are present as well as more
effectively debride a wound under fluorescence visualisation. These
are fundamental areas of everyday wound care that have remained
suboptimal for too long, until now,” says Dr. Ralph DaCosta,
Founder, Chief Scientific Officer and Director, MolecuLight
Inc.
An estimated 2 million people are living with a chronic wound
across Europe and an estimated 16% of all chronic wounds remain
unresolved after a year or longer.9,10,11 Ensuring wounds are
appropriately diagnosed and treated is a priority for healthcare
providers across Europe, reducing cost and improving outcomes for
patients.
“Not only has the MolecuLight i:X transformed my
department’s clinical decision making in terms of targeting
sampling and debridement and improving antimicrobial stewardship,
but the benefit to patients has also been exciting to see,” says
Rosemary Hill*, Canadian Wound Ostomy Continence Nurse Clinician,
Lions Gate Hospital, Vancouver. “By being able to engage patients
in their wound healing progress, and by showing them the real-time
images, we can reduce anxiety, and provide reassurance regarding
the diminishing burden of bacteria.”
The MolecuLight i:X Imaging Device is approved by Health
Canada (Medical License #95784) and has CE Marking (Certificate #
G1160292355002) for sale in the European Union. The MolecuLight
i:X Imaging Device is not available in the US.
Full press pack is available at:
http://www.smith-nephew.com/news-and-media/media-releases/news/european-launch-of-handheld-imaging-technology-heralds-new-era-of-evidence-based-decision-making
- ends –
About Smith & Nephew Smith & Nephew is a global
medical technology business dedicated to helping healthcare
professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew has more
than 15,000 employees and a presence in more than 100 countries.
Annual sales in 2016 were almost $4.7 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).For more information
about Smith & Nephew, please visit our website
www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit
SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce wound infection,
please visit www.closertozero.com
Forward-looking Statements This document may contain
forward-looking statements that may or may not prove accurate. For
example, statements regarding expected revenue growth and trading
margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target",
"consider" and similar expressions are generally intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that could cause actual results to differ materially from
what is expressed or implied by the statements. For Smith &
Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers; competition for qualified personnel; strategic actions,
including acquisitions and dispositions, our success in performing
due diligence, valuing and integrating acquired businesses;
disruption that may result from transactions or other changes we
make in our business plans or organisation to adapt to market
developments; and numerous other matters that affect us or our
markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith & Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith & Nephew's most recent annual
report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
About MolecuLight Inc.
MolecuLight Inc. is a privately owned, Canadian medical
imaging company delivering real-time fluorescence image-guidance
solutions that provide clinicians with new information about wound
bacterial burden and wound surface area to assist clinicians in
making improved diagnostic and treatment decisions.
The MolecuLight i:X is manufactured by MolecuLight® Inc.
MaRS Centre, South Tower 101 College St., Suite 200 Toronto, ON M5G
1L7 CanadaT +1 647.362.4684 F +1
647.362.4730www.moleculight.com
® Registered trademark acknowledged
[tm] All trademarks acknowledgedMolecuLight i:X and Look
to Heal are registered trademarks of MolecuLight Inc in Canada, the
US and the UK. MolecuLight DarkDrape is a registered trademark of
MolecuLight® Inc in Canada. Other jurisdictions pending
The MolecuLight i:X is distributed by Smith & Nephew
Wound ManagementSmith & Nephew Medical Ltd, 101 Hessle Road,
Hull HU3 2BN, UKT +44 (0) 1482 225181 F +44 (0) 1482
328326www.smith-nephew.com All Trademarks
acknowledged©October 2017 Smith & NephewAWM-AWD-11878
References:
1. DaCosta RS et al. Point-of-care autofluorescence imaging for
real-time sampling and treatment guidance of bioburden in chronic
wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).
2. MolecuLight Inc. PN 1189 MolecuLight i:X User Manual.
2016.
3. MolecuLight Inc. Case Study 0051 Track Wound Size and
Bacterial Presence with the MolecuLight i:X. 2016.
4. Hoeflok J et al. Pilot clinical evaluation of surgical site
infections with a novel handheld fluorescence imaging device.
Proceedings of the Annual Military Health System Research Symposium
(MHSRS); 2014 Aug 18- 21; Fort Lauderdale, FL.
5. Raizman R. Point-of-care fluorescence imaging device guides
care and patient education in obese patients with surgical site
infections. Presented at: CAWC 2016. Proceedings of the Annual
Canadian Association of Wound Care Conference (CAWC); 2016 Nov 3-6,
Niagara Falls, ON.
6. Raizman R. Fluorescence imaging positively predicts bacterial
presence and guides wound cleaning and patient education in a
series of pilonidal sinus patients. Proceedings of the Annual
Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.
7. Ottolino-Perry K et al. Improved detection of wound bacteria
using fluorescence image guided wound sampling in diabetic foot
ulcers. Int Wound J. 2017 Feb 28. doi: 10.1111/iwj.12717.
8. Posnett J et al. J. Wound Care (April 2009), The Resource
Impact of Wounds on Health-care Providers in Europe, vol.18
(4).
9. Lindholm C and Searle R. Wound management for the 21st
century: combining effectiveness and efficiency. Int Wound J. 2016
Jul;13 Suppl 2:5-15.
10. Siddiqui AR and Bernstein JM. Chronic wound infection: facts
and controversies. Clin Dermatol. 2010;28:519–26.
11. Vowden P. Hard-to-heal wounds made easy. Wounds
International, Schofield Healthcare Media Ltd: Norwich, UK, 2011;2.
URL: http:// www.woundsinternational.com.
* Rosemary Hill is a paid consultant of Smith & Nephew or
MolecuLight Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171211005434/en/
Media EnquiriesRachel
CunninghamRachel@roadcommunications.co.uk+4420 8995 5832orFabienne
MerletFabienne@roadcommunications.co.uk+4420 8995 5832orDave
SnyderSmith & Nephew+1 (978) 749-1440
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Sep 2023 to Sep 2024